Shortly after the completion of WES studies on these two virally associated head and neck cancers, it was immediately realized and genomically confirmed that previous scattered reports on low rates of TP53 and RB1 mutations are indeed key genomic features of these cancers [41,43,50,52]. This evidence concerns the gene TP53 and head and neck cancer.